GURU.Markets stock price, segment price, and overall market index valuation
The company's share price ProPhase Labs Inc.
ProPhase Labs has transformed itself from a dietary supplement manufacturer into a diagnostic and laboratory services company. Its stock price reflects this transformation, which received a major boost during the pandemic thanks to COVID testing.
Share prices of companies in the market segment - Medanalysis
ProPhase Labs is a diversified company that produces over-the-counter medications and dietary supplements, as well as provides genomic and diagnostic testing services. We've classified it as a "Medanalysis" company. The chart below shows the dynamics of the diagnostics sector.
Broad Market Index - GURU.Markets
ProPhase Labs is a diversified company that provides genetic and diagnostic testing services and manufactures dietary supplements. As a unique player, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with ProPhase Labs' performance to assess the state of this sector.
Change in the price of a company, segment, and market as a whole per day
PRPH - Daily change in the company's share price ProPhase Labs Inc.
ProPhase Labs, Inc.'s daily price change reflects volatility in the diagnostic services sector. The metric is sensitive to demand for its tests (including COVID-19) and news about business diversification.
Daily change in the price of a set of shares in a market segment - Medanalysis
ProPhase Labs, Inc. is a diversified healthcare company. This chart highlights the sector's high volatility. Comparing it to PRPH, with its businesses ranging from diagnostics to dietary supplements, helps us understand how diversification impacts its stability.
Daily change in the price of a broad market stock, index - GURU.Markets
ProPhase Labs provides medical diagnostics and over-the-counter drug manufacturing services. Its business operates at the intersection of several healthcare segments. Its stock price reflects these trends and contributes uniquely to the overall volatility landscape.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization ProPhase Labs Inc.
ProPhase Labs, Inc.'s year-over-year performance tells the story of its transformation from an over-the-counter cold medicine maker to a diversified diagnostics and genomics company. Its 12-month market cap reflects its success in providing tests for COVID-19 and other diseases, a new bet for the future.
Annual dynamics of market capitalization of the market segment - Medanalysis
ProPhase Labs, Inc. is a diversified company providing both diagnostic services and consumer healthcare products. The chart illustrates how its unique combination of stable consumer businesses and more volatile diagnostics impacts its overall performance in the healthcare sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
ProPhase Labs is a transformational company: from a COVID test maker to a genomics company. Its performance relative to the market demonstrates whether investors have bought into this strategic pivot. Outperforming the market means the new business model is perceived as more promising and capable of generating growth.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization ProPhase Labs Inc.
ProPhase Labs provides diagnostic testing services and has a portfolio of consumer products. Its monthly sales reflect demand for its tests, which can be seasonal (for example, for the flu), and sales of its dietary supplements.
Monthly dynamics of market capitalization of the market segment - Medanalysis
ProPhase Labs is a diversified company that produces over-the-counter medications and dietary supplements, as well as provides genomic and diagnostic testing services. The chart below shows the overall dynamics in the medical analysis sector, reflecting the growing demand for personalized diagnostics.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Stocks in diagnostics and consumer health can be defensive. The chart below shows general market fluctuations. Does ProPhase Labs demonstrate this stability, or does its diversified model make it more volatile?
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization ProPhase Labs Inc.
ProPhase Labs, a diversified diagnostic services and nutritional supplement developer, is responding to healthcare news. Weekly stock performance reflects demand for its tests (such as genetic tests), as well as the development of its R&D programs and the commercial success of its consumer products.
Weekly dynamics of market capitalization of the market segment - Medanalysis
ProPhase Labs, like other companies in the medical diagnostics sector, is dependent on overall healthcare trends. Demand for tests and genetic analysis are common factors for all companies. The chart below shows how ProPhase Labs' diversified business is performing compared to the industry average.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
ProPhase Labs, Inc., as a healthcare company, can demonstrate defensive qualities by moving out of sync with the broader market. Demand for its diagnostic services is less dependent on economic cycles. The chart will help assess whether PRPH truly represents a safe haven during periods of general market turbulence.
Market capitalization of the company, segment and market as a whole
PRPH - Market capitalization of the company ProPhase Labs Inc.
ProPhase Labs' market capitalization is a story of transformation. Originally a manufacturer of over-the-counter cold remedies, the company pivoted to diagnostic services and testing (especially during the pandemic). Its market capitalization reflects how investors view this new business model and its potential for growth post-pandemic.
PRPH - Share of the company's market capitalization ProPhase Labs Inc. within the market segment - Medanalysis
ProPhase Labs is a diversified company that produces dietary supplements and provides genomic and diagnostic testing services. Its sector share reflects this hybrid model. The chart shows how the market values its various business lines, from over-the-counter products to advanced diagnostics.
Market capitalization of the market segment - Medanalysis
ProPhase Labs provides diagnostic testing services and also produces dietary supplements. The chart below shows the market capitalization of the medical analysis sector. This is the valuation of a diversified company operating in both healthcare and consumer markets.
Market capitalization of all companies included in a broad market index - GURU.Markets
ProPhase Labs is a diversified company that produces both over-the-counter supplements and provides diagnostic and genomic testing. Its market capitalization reflects this hybrid model. The chart below shows the weightings of these diversified companies.
Book value capitalization of the company, segment and market as a whole
PRPH - Book value capitalization of the company ProPhase Labs Inc.
ProPhase Labs's material foundation is a network of diagnostic laboratories. The company's book value reflects its laboratory equipment for a wide range of tests (including genetic ones), as well as its manufacturing capacity for dietary supplements. The chart below shows how the company has transformed its foundation, becoming a diversified medical holding company.
PRPH - Share of the company's book capitalization ProPhase Labs Inc. within the market segment - Medanalysis
ProPhase Labs provides diagnostic services through its network of laboratories. This infrastructure is its main tangible asset. The S_BCap_Seg chart shows the company's share of the medical testing sector.
Market segment balance sheet capitalization - Medanalysis
ProPhase Labs provides diagnostic testing services and owns a line of dietary supplements. Its business requires certified laboratories and manufacturing facilities. The book value chart shows how these tangible assets form the foundation of its diversified model.
Book value of all companies included in the broad market index - GURU.Markets
ProPhase Labs is a diversified diagnostic and pharmaceutical company. Its book value reflects its network of clinical laboratories, production facilities for dietary supplements, and R&D. This multifaceted asset base allows it to operate in both service and product development.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - ProPhase Labs Inc.
ProPhase Labs provides diagnostic testing services and owns a portfolio of over-the-counter medications. Its balance sheet reflects its laboratories and inventory. Its market capitalization is a valuation of the sum of its parts, which has fluctuated significantly depending on demand for COVID-19 tests.
Market to book capitalization ratio in a market segment - Medanalysis
ProPhase Labs provides diagnostic and laboratory services and also has a pharmaceutical division. It is a diversified business. The chart shows how the market values the sum of its parts compared to their combined book value.
Market to book capitalization ratio for the market as a whole
ProPhase Labs provides diagnostic testing services and owns a portfolio of over-the-counter medications. Its valuation is the sum of the values of these two distinct businesses. The chart shows how the market values this diversified healthcare company.
Debts of the company, segment and market as a whole
PRPH - Company debts ProPhase Labs Inc.
ProPhase Labs, a diversified diagnostic and laboratory services company, uses debt for expansion and acquisitions. This chart shows how the company is funding the acquisition of new laboratories and technologies, as well as investing in marketing its services, aiming to become a major player in the diagnostics market.
Market segment debts - Medanalysis
ProPhase Labs transformed itself from an over-the-counter (OTC) manufacturer into a diagnostic and genomics services company. This strategic shift required investments in laboratory capacity and technology. This chart illustrates how its financial structure changed during this transformation.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio ProPhase Labs Inc.
ProPhase Labs provides diagnostic testing services and owns a portfolio of consumer healthcare products. This chart shows how the diversified company manages its capital. Debt levels may reflect investments in expanding laboratory capacity or marketing its brands, which speaks to its priorities.
Market segment debt to market segment book capitalization - Medanalysis
ProPhase Labs provides medical diagnostics and testing services. This chart for the medical testing sector shows how companies fund their laboratories and the development of new tests. It helps assess how aggressively the company is investing in expanding its capabilities in a highly competitive environment.
Debt to book value of all companies in the market
ProPhase Labs is a diversified company providing diagnostic testing services (including COVID-19) and manufacturing consumer healthcare products. The debt-to-book value chart helps assess the overall health of the healthcare sector and consumer spending, which drives demand for ProPhase Labs' services and products.
P/E of the company, segment and market as a whole
P/E - ProPhase Labs Inc.
ProPhase Labs is a diversified company that manufactures over-the-counter medications and provides diagnostic and laboratory services. This chart reflects the valuation of its hybrid model. This metric is driven by both sales of its consumer products and the volume of lab tests, including COVID-19 and other tests.
P/E of the market segment - Medanalysis
ProPhase Labs, Inc. is a diversified healthcare company. This chart shows the average P/E for the industry. Comparing the company's P/E to this metric helps understand how the market views its hybrid model (diagnostics and consumer goods)—whether it's more or less stable than that of focused companies.
P/E of the market as a whole
ProPhase Labs has transformed itself from an over-the-counter cold and flu medicine maker into a diversified company providing diagnostic services (including COVID tests) and genomic testing. This chart reflects sentiment in the healthcare sector. The company's valuation hinges on the success of its new strategy and its ability to compete in the rapidly growing genetic testing market.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company ProPhase Labs Inc.
ProPhase Labs provides diagnostic testing services and has a portfolio of consumer healthcare products. The chart shows future revenue expectations, which depend on demand for tests (e.g., for COVID-19 and influenza) and sales of its over-the-counter products.
%20P%2FE%20ProPhase%20Labs%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-ProPhase-Labs-Inc.&v=1772547511862 "Chart of the company's future (projected) P/E ProPhase Labs Inc.")
Future (projected) P/E of the market segment - Medanalysis
ProPhase Labs provides a wide range of medical services, from diagnostic testing to contract pharmaceutical manufacturing. This chart shows how its future profit expectations compare to the industry average, reflecting its diversified business model and ability to adapt to changing healthcare needs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Medanalysis&v=1772547511930 "Future (projected) P/E graph of the market segment - Medanalysis")
Future (projected) P/E of the market as a whole
ProPhase Labs provides diagnostic testing services and has a line of consumer health products. The company's business has transformed during the pandemic. Its challenge now is to find a sustainable business model in the post-pandemic world, making its story unique among general market trends.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772547511974 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit ProPhase Labs Inc.
ProPhase Labs, Inc. is a diversified company that provides diagnostic and laboratory services and manufactures over-the-counter medications and dietary supplements. The company's revenue comes from multiple sources and can fluctuate significantly depending on demand, such as for COVID-19 tests. This chart shows how the company adapts to changing market needs.
Profit of companies in the market segment - Medanalysis
ProPhase Labs, Inc. is a diversified company that provides genomic testing and diagnostics services and manufactures over-the-counter medications and nutritional supplements. This chart reflects the profitability of the healthcare analytics sector. Its business model combines stable revenue from consumer products with growth in high-tech diagnostics.
Overall market profit
ProPhase Labs provides laboratory diagnostics services and owns a portfolio of over-the-counter (OTC) medications. Demand for diagnostic tests can be volatile (as is the case with COVID-19), while OTC sales are more stable. This chart illustrates the general economic cycles against which ProPhase operates in specific healthcare niches.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company ProPhase Labs Inc.
ProPhase Labs provides clinical diagnostics and testing services and also produces over-the-counter medications and dietary supplements. This chart reflects analysts' combined expectations for these two businesses. It shows how the market views the prospects for both the company's diagnostics business and its consumer segment.
%20profit%20of%20the%20company%20ProPhase%20Labs%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-ProPhase-Labs-Inc.&v=1772547512258 "Graph of future (projected) profit of the company ProPhase Labs Inc.")
Future (predicted) profit of companies in the market segment - Medanalysis
ProPhase Labs, Inc. is a diversified company providing diagnostic and genomic services and manufacturing over-the-counter medications. This chart shows profitability forecasts for the healthcare analytics sector. It reflects growth expectations for the personalized medicine and laboratory diagnostics market.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Medanalysis&v=1772547512290 "Graph of future (predicted) profits of companies in a market segment - Medanalysis")
Future (predicted) profit of the market as a whole
ProPhase Labs provides diagnostic and laboratory services. Demand for medical tests is generally stable, but its growth depends on innovation and healthcare budgets. The overall market revenue forecast, shown in the graph, influences these budgets and overall investment activity in the healthcare sector.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772547512408 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - ProPhase Labs Inc.
ProPhase Labs provides diagnostic testing services and owns a portfolio of consumer healthcare products. Its revenue is a hybrid of testing and sales revenue. The P/S ratio helps evaluate both segments, demonstrating how the market views its diversified business model.
P/S market segment - Medanalysis
ProPhase Labs provides a wide range of medical services and products, including diagnostic testing (including for COVID-19) and over-the-counter (OTC) medications. Their business is diversified across the healthcare sector. This chart shows how the market views their hybrid model and their ability to generate revenue from multiple streams.
P/S of the market as a whole
ProPhase Labs provides diagnostic testing services and owns a portfolio of over-the-counter medications. The company's revenue can fluctuate significantly depending on demand for tests (for example, during pandemics). This chart shows the average revenue estimate, which helps understand how the market values a hybrid business with irregular revenues.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company ProPhase Labs Inc.
ProPhase Labs provides diagnostic testing services and also produces over-the-counter medications and dietary supplements. The company has diversified its business. This chart reflects investor expectations for total future revenue, which combines stable consumer product sales with more volatile diagnostic revenue.
%20P%2FS%20ProPhase%20Labs%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-ProPhase-Labs-Inc.&v=1772547512658 "The graph of the company's future (projected) P/S ProPhase Labs Inc.")
Future (projected) P/S of the market segment - Medanalysis
ProPhase Labs, Inc. is a diversified company engaged in diagnostics, genomic testing, and consumer healthcare products. This chart shows how the market values its future revenue across various businesses. It compares it to other companies in the medical testing sector, reflecting its transformation into a biomedical technology company.
%20P%2FS%20market%20segment%20graph%20-%20Medanalysis&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Medanalysis&v=1772547512665 "Future (projected) P/S market segment graph - Medanalysis")
Future (projected) P/S of the market as a whole
ProPhase Labs is a diversified company that provides diagnostic services (including COVID-19 tests) and produces dietary supplements. This chart shows overall market revenue expectations, and PRPH illustrates how companies can adapt their businesses to changing conditions, such as the pandemic, and find new revenue streams.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772547512695 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales ProPhase Labs Inc.
ProPhase Labs, Inc. is a diversified company operating in diagnostics, genomics, and over-the-counter (OTC) pharmaceuticals. This chart shows its revenue, which is generated from both laboratory testing services (including genomic tests) and sales of dietary supplements and cold remedies.
Sales of companies in the market segment - Medanalysis
ProPhase Labs provides diagnostic testing services and owns a portfolio of over-the-counter medications. This chart clearly breaks down its revenue between these two segments. This allows investors to assess which—services or products—contributes more to overall performance.
Overall market sales
ProPhase Labs provides diagnostic testing services and owns consumer brands. The diagnostics business can be volatile (as demonstrated by COVID-19), while consumer goods are more stable. This graph of the overall economic situation influences the second part, but the first operates according to its own laws, dependent on the epidemiological situation.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company ProPhase Labs Inc.
ProPhase Labs provides laboratory diagnostic services and manufactures and sells over-the-counter medications and dietary supplements. Its revenue forecast reflects expected demand for its diagnostic tests and consumer products. This chart shows how analysts assess its diversified business model.
%20sales%20of%20the%20company%20ProPhase%20Labs%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-ProPhase-Labs-Inc.&v=1772547512754 "Schedule of future (projected) sales of the company ProPhase Labs Inc.")
Future (projected) sales of companies in the market segment - Medanalysis
ProPhase Labs provides diagnostic testing services and owns a portfolio of over-the-counter (OTC) medications. This chart shows projected revenue for the entire healthcare analytics sector. It reflects demand for laboratory services, which can fluctuate significantly depending on the epidemiological situation, impacting one of ProPhase's key revenue sources.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Medanalysis&v=1772547512789 "Schedule of future (projected) sales of companies in the market segment - Medanalysis")
Future (projected) sales of the market as a whole
ProPhase Labs provides diagnostic testing services and has a portfolio of consumer health products. Demand for its tests can be situational (as during the pandemic), while demand for its products depends on consumer trends. This graph of overall consumer expectations reflects people's willingness to spend on health, which is important for the company's product segment.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772547512905 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality ProPhase Labs Inc.
ProPhase Labs provides diagnostic testing services and owns a portfolio of consumer healthcare products. This chart illustrates how diversification impacts results. Its profitability depends on testing volumes, which can fluctuate widely, and on stable sales of over-the-counter medications.
Market segment marginality - Medanalysis
ProPhase Labs, Inc. is a diversified company providing diagnostic testing services (including COVID-19) and manufacturing over-the-counter medications and dietary supplements. This chart shows the average profitability in the medical testing sector. It helps assess how the company manages its various business segments to maintain overall profitability.
Market marginality as a whole
ProPhase Labs, Inc. provides diagnostic testing services and has a portfolio of consumer healthcare products. The company has transformed significantly during the pandemic, focusing on COVID-19 testing. This gross margin chart illustrates how external shocks can fundamentally alter business models and create new revenue streams.
Employees in the company, segment and market as a whole
Number of employees in the company ProPhase Labs Inc.
ProPhase Labs is a diversified company engaged in the production of dietary supplements and the provision of diagnostic services. Its staff is engaged in both manufacturing and clinical laboratories. This chart reflects the combined scale of its two distinct business segments.
Share of the company's employees ProPhase Labs Inc. within the market segment - Medanalysis
ProPhase Labs, Inc. provides diagnostic testing services and manages a portfolio of consumer healthcare products. This chart illustrates its diversified business. It reflects the proportion of laboratory technicians, scientists, and marketing and sales professionals working in both diagnostics and over-the-counter (OTC) pharmaceuticals that ProPhase employs.
Number of employees in the market segment - Medanalysis
ProPhase Labs, Inc. is a diversified company providing diagnostic services and manufacturing consumer healthcare products. This chart shows employment in the healthcare analytics sector. Growth in this area reflects increased demand for lab tests, which was particularly noticeable during the pandemic, and diversification into related fields.
Number of employees in the market as a whole
ProPhase Labs, Inc. is a diversified company operating in diagnostics, genomic testing, and consumer healthcare. Integration of various fields in medicine is a current trend. This chart shows overall employment, and companies like these demonstrate how technology synergies create new market opportunities.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company ProPhase Labs Inc. (PRPH)
ProPhase Labs provides diagnostic services, a sector that requires both equipment and qualified personnel. The metric on this chart reflects the balance between the cost of laboratory equipment (capital intensity) and the team's expertise (intellectual capital).
%20of%20the%20company%20ProPhase%20Labs%20Inc.%20(PRPH)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-ProPhase-Labs-Inc.-PRPH&v=1772547513401 "Chart of market capitalization per employee (in thousands of dollars) of the company ProPhase Labs Inc. (PRPH)")
Market capitalization per employee (in thousands of dollars) in the market segment - Medanalysis
ProPhase Labs provides clinical diagnostic services. Its market value per employee reflects the efficiency of its laboratories and the demand for its tests. Comparisons with other diagnostic companies help assess how effectively it utilizes its equipment and personnel to generate profit.
%20by%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Medanalysis&v=1772547513415 "Market capitalization per employee (in thousands of dollars) by market segment - Medanalysis")
Market capitalization per employee (in thousands of dollars) for the overall market
ProPhase Labs provides diagnostic testing services and has a line of over-the-counter medications. This chart reflects how the market evaluates the company's ability to operate in two distinct healthcare segments: service provision (laboratory tests) and product sales (medications).
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772547513486 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company ProPhase Labs Inc. (PRPH)
ProPhase Labs is a chameleon company. Formerly a dietary supplement manufacturer, it earned millions from COVID testing (CLIA-certified labs) during the pandemic. This graph likely shows a huge spike followed by a decline. It reflects how the team monetized this opportunity and is now seeking new revenue streams.
%20Chart%20ProPhase%20Labs%20Inc.%20(PRPH)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-ProPhase-Labs-Inc.-PRPH&v=1772547513560 "Company Profit Per Employee (in thousands of dollars) Chart ProPhase Labs Inc. (PRPH)")
Profit per employee (in thousands of dollars) in the market segment - Medanalysis
ProPhase Labs, Inc. is a diversified company providing genomic sequencing and diagnostic testing services, as well as manufacturing over-the-counter medications. This chart reflects the effectiveness of their multi-pronged strategy. It shows how successfully the company generates combined revenue from its diverse yet complementary healthcare businesses.
%20in%20the%20market%20segment%20-%20Medanalysis&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Medanalysis&v=1772547513594 "Chart of profit per employee (in thousands of dollars) in the market segment - Medanalysis")
Profit per employee (in thousands of dollars) for the market as a whole
ProPhase Labs, Inc. is a diversified company that has expanded from dietary supplements to diagnostic services (COVID tests), and now into pharmaceuticals. This metric will fluctuate widely. During the pandemic, earnings per employee were high due to testing. Now, it reflects the efficiency of managing a diversified portfolio, including R&D expenses.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772547513676 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee ProPhase Labs Inc. (PRPH)
ProPhase Labs provides diagnostic testing services and owns consumer brands. This chart demonstrates the effectiveness of its diversified model. Revenue per employee depends on both testing volume (which can be highly volatile) and stable consumer product sales.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-ProPhase-Labs-Inc.-PRPH&v=1772547513720 "Sales chart per company employee ProPhase Labs Inc. (PRPH)")
Sales per employee in the market segment - Medanalysis
ProPhase Labs (PRPH) is a company that has transformed itself from an over-the-counter (OTC) product manufacturer (Cold-Eeze) into a diversified provider of diagnostic services (COVID tests) and genomic testing. This chart shows the average revenue per employee in the segment. Comparing PRPH to this benchmark demonstrates how productive their new revenue model is.
Sales per employee for the market as a whole
ProPhase Labs (PRPH) is a diversified company that has shifted focus from dietary supplements to diagnostic testing (COVID-19), and now to genomics. This metric has been extremely volatile: it spiked during the pandemic (testing) and is now declining. The chart shows their efforts to find a new, stable source of revenue.
Short shares by company, segment and market as a whole
Shares shorted by company ProPhase Labs Inc. (PRPH)
ProPhase Labs transformed itself from a cold lozenge maker into a major diagnostic lab during the COVID-19 pandemic. This chart shows bets that its core business (COVID testing) has died. Bears believe the company won't be able to replace this revenue, and its stock will return to pre-COVID levels.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-ProPhase-Labs-Inc.-PRPH&v=1772547514022 "Short Shares Chart for the Company ProPhase Labs Inc. (PRPH)")
Shares shorted by market segment - Medanalysis
ProPhase Labs (PRPH) is a transformative company. It used to sell cold lozenges, became a COVID lab during the pandemic, and is now focused on oncology. This chart highlights the pessimism in the sector. The surge in shorts across the industry is a bet that PRPH won't be able to re-invent itself. Investors are skeptical of its oncology business and expect the company to run out of cash after its COVID-19 revenue collapses.
Shares shorted by the overall market
ProPhase Labs (PRPH) is a diversified company (diagnostics, dietary supplements). When this fear indicator rises, investors fear that during a recession (1) consumers will abandon dietary supplements and (2) routine testing volumes will decline. Investors are selling small, complex stories.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator ProPhase Labs Inc. (PRPH)
ProPhase Labs has transformed from a dietary supplement manufacturer into a diagnostic lab (genomics, COVID testing). This chart shows the "pulse" of this transformation. The "temperature" was "overheated" at the peak of the pandemic due to testing, and now the indicator shows how much the market has cooled and how it values their new genomics business.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-ProPhase-Labs-Inc.-PRPH&v=1772547514292 "RSI 14 indicator chart for the company's stock ProPhase Labs Inc. (PRPH)")
RSI 14 Market Segment - Medanalysis
ProPhase Labs is a diversified company. Historically known for its over-the-counter cold remedies, they are now focused on laboratory diagnostics (including COVID tests) and genomic testing. This chart reflects the overall sentiment in the medical testing and diagnostics sector and helps assess how the market views the industry as a whole.
RSI 14 for the overall market
ProPhase Labs (PRPH), a testing manufacturer, sees both hype and fear in this chart. In times of euphoria (or pandemic), demand for "safety" is enormous. In times of "panic" (a return to normal), its clients cut their budgets for "optional" testing, and demand for its services falls.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PRPH (ProPhase Labs Inc.)
ProPhase Labs (PRPH) is a diversified company that grew rapidly in COVID testing and is now expanding into nutraceutical (MLM) and pharmaceutical businesses. This chart shows the average 12-month forecast, reflecting analyst expectations for the company's ability to replace testing revenue with new businesses.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PRPH-ProPhase-Labs-Inc.&v=1772547514524 "A chart showing analyst consensus forecasts for the expected stock price. PRPH (ProPhase Labs Inc.)")
The difference between the consensus estimate and the actual stock price PRPH (ProPhase Labs Inc.)
ProPhase Labs is a company that has completely transformed itself. The former manufacturer of cold lozenges (Cold-EEZE) has become a major diagnostic lab (COVID testing) and is expanding its R&D. This chart shows the growth potential analysts see. It measures the gap between the price and the forecast, reflecting their confidence in this new business model.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PRPH-ProPhase-Labs-Inc.&v=1772547514615 "A chart showing the difference between the consensus forecast and the actual stock price. PRPH (ProPhase Labs Inc.)")
Analyst consensus forecast for stock prices by market segment - Medanalysis
ProPhase Labs is a chameleon company. Having sold its renowned brand (Cold-EEZE), it transformed itself into a diagnostic lab (COVID tests, genomics). This chart reflects analysts' general expectations for the entire medical testing sector. It shows whether experts believe the genetic testing market will grow.
Analysts' consensus forecast for the overall market share price
ProPhase Labs is a transformative company. Historically known for its cold lozenges (Cold-EEZE), it now focuses on genetic testing and diagnostics. This chart shows the overall "risk appetite" in the market. For ProPhase, a company searching for a new business model, overall optimism (risk appetite) is important to funding their ambitious move into the genomics sector.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index ProPhase Labs Inc.
ProPhase Labs is a chameleon company. Historically, they sold a cold medicine (Cold-Eeze). During the pandemic, they relaunched themselves as a giant diagnostic lab (COVID testing). This chart is a summary of their second life. It reflects their (disappearing) revenue from COVID testing and their desperate attempts to find new, sustainable business in R&D or genomics.
AKIMA Market Segment Index - Medanalysis
ProPhase Labs (PRPH) has transformed itself from an over-the-counter (OTC) product maker (Cold-Eeze) into a diversified diagnostics and genomics company. They offer a wide range of tests (including COVID-19) and sequencing services. The chart shows the segment's average index, helping investors assess how successful this transformation is compared to the industry average.
The AKIM Index for the overall market
ProPhase Labs is a diversified company: diagnostics (genetics), dietary supplement production (Cold-EEZE), and biopharmaceuticals. This chart, reflecting the market average, provides a macro backdrop. It helps assess how ProPhase Labs, transforming from a lozenge maker into a genomics company, fits into the overall picture.
